On one hand, the ampules and the company logos suggested a research and laboratory focus, listing chemical properties, formulas, etc, with product labels indicating “research use only.” By contrast, most product descriptions provided by the peptide dealers emphasized the effects of GLP‐1 agonists, describing preclinical and clinical studies on potential health-related benefits (eg, beta cell protection, weight loss, diabetes, appetite reduction, and neurodegenerative disease). This evidence concerns the gene GCG and neurodegenerative disease.